DocWire News Editors

DocwireNews

The findings of the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF) suggest that dapagliflozin is effective in the treatment of reduced ejection fraction (HFrEF) in patients with and without type 2 diabetes (T2D).In this study, researchers randomized 4,744 patients (mean age, 66, 23% female) from 410 centers across 20 countries from February 15, 2017, through August 17, 2018. The population of interest were required to be New York Heart Association (NYHA) functional class II-IV, with a left ventricular ejection fraction (LVEF) of 40% or lower, having a plasma NT-proBNP of at least 600 mg/mL, and undergoing standard drug and device therapy for HF. Overall, 68% of patients were in NYHA class II, mean LVEF was 31% and the median NT-proBNP 1437pg/mL. Also, 56% of patients had an ischemic etiology and 42% had a history of type 2 diabetes (T2D). For the study&rsquo;s key endpoint, the researchers said that dapagliflozin would need show superiority for the primary composite outcome of a first episode of worsening heart failure (HF) or death from cardiovascular (CV) causes.The secondary outcomes of this study were defined as: the composite of HF hospitalization or CV death; the total number of recurrent HF hospitalizations (including repeat admissions) and CV deaths; change from baseline to 8-months in the total symptom score of the Kansas City Cardiomyopathy Questionnaire (KCCQ); the incidence of a composite worsening renal function outcome and; and all-cause mortality.According to the results, dapagliflozin reduced the risk of worsening heart failure events as well as CV mortality while improving symptoms in patients with HFrEF. The researchers reported a reduction in the primary composite outcome in patients with diabetes (HR=0.75; 95% CI, 0.63 to 0.90) and also in patients with no diabetes (HR=0.73; 95% CI, 0.60 to 0.88). Reductions were also observed in the individual components of the primary outcome such as CV death (dapagliflozin lowered risk in both diabetic and non-diabetic cohorts) and worsening HF events (again in both cohorts).&ldquo;When added to standard therapy, dapagliflozin reduced the risk of worsening HF events and CV death, and improved symptoms, in patients with HFrEF, both with and without T2D,&rdquo; John J.V. McMurray, BHF, of the Cardiovascular Research Centre in Glasgow, U.K., concluded in the presentation. &ldquo;The relative and absolute risk reductions in death and hospitalization were substantial, clinically important, and consistent in patients with and without T2D. Dapagliflozin was well tolerated and the rate of treatment discontinuation was low in patients with and without T2D.&rdquo;Dapagliflozin was recently granted a Fast Track designation by the FDA. The designation, according to the <a href="https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-heart-failure.html">manufacturer</a>, allows for the accelerated development and research of dapagliflozin to reduce the risk of CV death or worsening heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or with preserved ejection fraction (HFpEF).

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

DAPA-HF: The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial

AHA 2019

The findings of the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF) suggest that dapagliflozin is effective in the treatment of reduced ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe